Latest Feature

Sanovas CEO Larry Gerrans and the MicroCam technology

Sanovas' new MicroCam plug-and-play endoscopic imaging system paves the way for a paradigm shift toward linear medical devices for natural orifice surgery, CEO Larry Gerrans tells MassDevice.com.

Data and Healthcare

A quartet of healthcare giants including UnitedHealth, the largest single health insurer in the U.S., joins forces for the SharedClarity project, aiming to leverage their combined Big Data to get the best devices for the best prices.

The E-bay of medical devices: A conversation with Aptitude's Troy Kirchenbauer

MassDevice talks disruptive business models in the medical device and hospital world with Novation executive and aptitude vice president Troy Kirchenbauer

Emergency Preparedness Checklist

Although current quality systems are likely sufficient, the FDA should look to lessons learned from recent catastrophes in developing risk mitigation strategies to better protect medical devices and related systems, an agency panel says.

Biomet CEO (and blogger) Jeff Binder takes a strong stand on gain-sharing

Biomet CEO Jeff Binder tells MassDevice.com why gain sharing is bad for the medical device business and how the best is yet to come for the orthopedics sector.

Subscribe to the MassDevice Weekly Roundup

Email:

Is Valeant About To Make A Bold Bid For Bausch & Lomb?

May 24, 2013 by MassDevice

MassDevice columnist Stephen Simpson on rumors that Valeant may be prepping a $9 billion bid for Bausch+Lomb

Bausch

By Stephen Simpson

Never let it be said that Valeant (NYSE: VRX) management is shy about doing deals. With a roster of past deals including Biovail, Cephalon, OraPharma, and Medicis, Valeant claims that better than 80% of its deals have attained the 20% internal return target it uses to evaluate potential transactions. If rumors out Friday prove true, Valeant is about to bag its biggest target yet in what would be a particularly bold move.

MassDevice.com +7 | The top 7 med-tech stories for the week of May 20, 2013

May 24, 2013 by Arezu Sarvestani

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

The FDA: Now more popular than the IRS, Federal Reserve and Dept. of Homeland Security

May 24, 2013 by Brian Johnson

A new Gallup poll shows that American's opinion of the FDA is on the upswing

American's view of the FDA are improving, according to a recent Gallup survey of opinions on federal agencies.

The federal watchdog agency received a net positive rating of 24%, according to the polling organization, putting it ahead of The Department of Homeland Security, Federal Reserve, Environmental Protection Agency and the Internal Revenue Service.

EuroPCR: Medtronic moving forward with its renal denervation study

May 24, 2013 by Sony Salzman

Medtronic finishes enrolling patients in a U.S. trial of its Simplicity renal denervation system to treat high blood pressure

Medtronic

Medtronic (NYSE:MDT) has wrapped up patient enrollment in its Symplicity HTN-3 trial to evaluate company's renal denervation system and support U.S. approval.

EuroPCR: Volcano, Boston Scientific team up for accurate stent placement study

May 24, 2013 by Sony Salzman

Volcano and Boston Scientific use their respective devices simultaneously for more accurate stent placement in a new study announced at EuroPCR

EuroPCR

Volcano Corporation (NSDQ:VOLC) and Boston Scientific (NYSE:BSX) announced a new, cosponsored Syntax study to test precision in stent placement.

The companies announced the upcoming study at the EuroPCR annual meeting in Paris, France.

EuroPCR: St. Jude's EnligHTN device shows promising 1-year trial results

May 24, 2013 by Sony Salzman

St. Jude presents 1-year data supporting its EnligHTN device for patients with drug-resistant high blood pressure


StJude

St. Jude Medical (NYSE:STJ) released results for its EnligHTN renal denervation system trial, which effectively lowered blood pressure in patients after 1 year.

Data from EnliGHTN I was presented at the annual EuroPCR meeting in Paris, France.

Legal: Intuitive Surgical wins jury trial in da Vinci training claim

May 24, 2013 by Sony Salzman

Jurors in Washington state vote 10-2 for Intuitive Surgical in the first of many lawsuits over the company's da Vinci robotic surgical system

IntuitiveSurgical

Intuitive Surgical (NSDQ:ISRG) won a legal victory in a patient injury lawsuit involving its da Vinci robotic surgical assist device.

FzioMed's post-surgical gel lands a regulatory win in Australia

May 24, 2013 by Sony Salzman

Aussie regulators give the green light to FizioMed's Dynavisc, an absorbable gel applied to tendons and nerves after surgery.

FzioMed

Privately held medical device maker FzioMed won Australian regulatory approval for its Dynavisc post-surgical gel, an absorbable gel applied to tendons and nerves to reduce adverse events after surgery.

The San Luis Obispo, Calif.-based company said the product is similar to Medtronic's (NYSE:MDT) Medishield, which has been on the market for more than 70 years.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp